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The authors describe a patient with known human immunodeﬁciency virus
(HIV)–1 infection who presented with two generalized seizures and was found
to have extensive white matter disease and a left/bilateral temporo-occipital
focal slowing on electroencephalography (EEG). There were no magnetic reso-
nance imaging (MRI) or cerebrospinal ﬂuid (CSF) indications for opportunistic
infection. Plasma viremia was controlled, whereas viral replication was un-
controlled in CSF. CSF-speciﬁc genotype-guided adaptation of the antiretro-
viral therapy in order to optimize central nervous system (CNS) penetration
resulted in clinical improvement and normalization of MRI and EEG. Our
case report illustrates the importance of individualized antiretroviral therapy
in HIV infected patients with neurological complications. Journal of NeuroVi-
rology (2008) 14, 78–84.
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Case report
In August 2003, a 40-year-old man with longstand-
ing human immunodeﬁciency virus (HIV)-1 infec-
tion presented with a ﬁrst-generalized tonic-clonic
seizure. HIV-infection was known since 1987 and
the patient was enrolled in a methadone program
since 1986. He took zidovudine monotherapy from
1993 to1997, and was on highly active antiretrovi-
ral therapy (HAART) since 1997. From 1997 to 2003
he was treated with lamivudine and stavudine com-
plemented with indinavir from 1997 to 1999, and
nelﬁnavir from 1999 to 2003 (Figure 1). He also had
a brief exposure to efavirenz, which was stopped
because of neuropsychiatric side effects. The pa-
tient’s nadir CD4+ T-cell count was 166/μl (11%)
before HAART initiation; but his CD4+ T cells rose
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rapidly and remained >400/μl since 1998 whereas
his viremia remained only partially controlled (al-
ways <1000 copies/ml from 1997 to 2004). He never
experienced any opportunistic infection or malig-
nancy. HIV plasma genotyping in 2003 revealed the
presence of the D30N and N88D/N mutation, which
mediate resistance to nelﬁnavir and the M184V and
T215Y mutation conferring resistance to lamivudine
and partial resistance to stavudine. However, be-
cause his viral load was always <1000 copies, the
patient chose to remain on his HAART regimen. At
the time of the ﬁrst seizure, the patient’s CD4+ T-
cell count was 794/μl (14%) and his plasma viral
load was 281 copies/ml. Magnetic resonance imag-
ing (MRI) revealed diffuse frontal and temporal white
matter T2-hyperintensities. Contrast-enhanced stud-
ies were negative. These ﬁndings were consistent
with HIV-1-associated encephalopathy and not sug-
gestive for opportunistic infection. The patient re-
mained otherwise asymptomatic and did not show
any signs of cognitive impairment. Twelve months
later his HAART regimen was changed for more
convenient dosing to once-daily ritonavir/atazanavir,
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Figure 1 Chronology of antiretroviral therapy with quantiﬁcation of CNS penetration. VL: viral load. AZT = zidovudine; d4T =
stavudine; 3TC = lamivudine; IDV = indinvavir; NFV = nelﬁnavir; rATV = ritonavir-boosted atazanavir; TDF = tenofovir; ddI =
didanosine; LPV = ritonavir-boosted lopinavir; NVP = nevirapine.
with didanosine and tenofovir. His plasma viral
load now became undetectable (<40 copies/ml). Two
months later he experienced another generalized
seizure, which prompted a neurological evaluation,
which was unremarkable without signs of cognitive
or memory impairment. Repeat MRI showed moder-
ate progression of the diffuse white matter disease
(Figure 2A). Electroencephalography (EEG) revealed
subtle background alterations with a bilateral
temporo-occipital focal slowing (Figure 3A).
Cerebrospinal ﬂuid (CSF) analysis revealed pleio-
cytosis (32 × 106/L), elevated protein (917mg/L), and
immunoglobulin G (IgG) (527 mg/L) and oligoclonal
bands. Serologic assays for borreliae, syphilis, her-
pes simplex virus, and varicella zoster virus (VZV)
were negative as well as polymerase chain reac-
tion (PCR) assays for Toxoplasma gondii, JC virus,
Epstein Barr virus, cytomegalovirus, and VZV. The
cerebrospinal ﬂuid (CSF) HIV viral load was 8896
copies/ml, whereas plasma viremia remained un-
detectable (<40 copies/ml). Genotyping of the CSF
virus revealed thymidine-analogue mutations M41L
and T215Y, conferring intermediate resistance to
zidovudine and low-level resistance to didanosine
and tenofovir, the A98G polymorphism on the re-
verse transcriptase gene, and L63P polymorphism
on the protease gene. Attempting to adapt the pa-
tient’s HAART for higher efﬁcacy against the HIV
quasispecies in central nervous system (CNS) and
for optimal CSF penetration, his regimen was now
changed to nevirapine, zidovudine and lamivudine,
and lopinavir/ritonavir. The patient was also started
on antiepileptic therapy with levetiracetam, which
he discontinued after 4 months. He has remained
seizure free for almost 3 years to date and still
shows no sign of cognitive impairment. A follow-
up MRI demonstrated normalization of previous T2-
hyperintensities with some widening of the lateral
ventricles probably indicating resolution of edema,
possibly unmasking some degree of subcortical brain
atrophy (Figure 2B). A follow-up EEG after 19months
had also almost normalized (Figure 3B). CSF analysis
12 months after switching to CNS-adapted HAART
showed resolution of pleiocytosis and reduction
in total protein (679 mg/L) and IgG (345 mg/L).
The CSF HIV viral load was now undetectable
(<50 copies/ml).
Discussion
Epileptic seizures are a frequent event in HIV-
infected patients. Before the ART-era, their annual
incidence was estimated up to 11% and in one study
even up to 17%, whereas a reduced frequency with
a prevalence of up to 6% was reported in the ART-
era (Dore et al, 1999; Kellinghaus et al, 2007; Levy
and Bredesen, 1988; Pascual-Sedano et al, 1999).
In almost 50% of cases, no causal opportunistic
disease was identiﬁed, suggesting a HIV-related
pathogenesis (Langford et al, 2003). The differen-
tial diagnosis in HIV-infected patients with seizures
comprises infections such as toxoplasmosis, cryp-
tococcal or tuberculous meningitis, and progressive
multifocal leukencephalopathy (PML) (Price, 1996).
Furthermore, CNS lymphoma and drugs used for
treatment of the HIV infection and metabolic alter-
ations such as renal or hepatic failuremay predispose
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Figure 2 T2-weighted MRI after the second seizure (A) and at 19-month follow-up (B). (A) No contrast-enhancing lesions are detected
on T1-weighted images (upper row), whereas mainly subcortical T2-hyperintense white matter abnormality is noted most prominently
in left frontal areas (white ellipse; lower row). Normalization of white matter signal intensity and improved differentiation of grey and
white matter is demonstrated on follow-up (B).
for seizures (Barton et al, 1992; D’Silva et al, 1995).
As the second seizure occurred in our patient after
changing the antiretroviral therapy, an immune re-
constitution syndrome might have also triggered it.
However, no increase of lymphocyte counts was de-
tected after modiﬁcation of the therapy and the MRI
showed no contrast-medium enhancement, both of
which argue against the possibility of seizures caused
by a immune reconstitution inﬂammatory syndrome
in the CNS (Venkataramana et al, 2006).
We therefore considered the seizures as secondary
manifestation of the HIV infection in CNS and initi-
ated an antiepileptic treatment with levetiracetam.
Levetiracetam has been reported to be efﬁcacious
in HIV-positive patients with HAART treatment
(Liedtke et al, 2004). It undergoes minor metabolism
by plasma hydrolases, but not by the liver, as it
does not interact with the hepatic cytochrome P450
(CYP450) enzyme function by which most protease
inhibitors and non-nucleoside reverse transcriptase
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Figure 3 Electroencephalogram after the second seizure (A) and at 19-month follow-up (B). (A) Electroencephalogram (EEG) withmodest
background alterations and intermittent focal slowing in both temporo-occipital regions, spreading also to the frontal regions (box). (B)
Follow-up EEG after adaptation of HAART, which showed almost complete resolution of background alterations and of the left-sided
focal slowing whereas a minor slowing still persists on the right temporo-occipital region (boxes).
inhibitors are metabolized. Interactions of antiretro-
viral agents and the well-known antiepileptic drugs
carbamazepine, phenytoin, and phenobarbital have
been described in HAART-treated patients, espe-
cially when protease inhibitors are given (Liedtke
et al, 2004; Bates et al, 2006). Valproic acid has been
discussed to have a potential neuroprotective effect
in HIV-associated cognitive impairment (Dou et al,
2003; Schiﬁtto et al, 2006). It is metabolized by the
hepatic CYP450 system (mainly the 2C9 isoform) and
is conjugated by the uridyl-glucuronyl transferase,
but has been reported to be save when given in com-
bination with the non-nucleoside reverse transcrip-
tase inhibitor efavirenz and the protease inhibitor
lopinavir (DiCenzo et al, 2004). In contrast, valproic
acid acts as a modest inhibitor of several CYP450
isoforms and might thereby prolong the elimination
half-time of antiretroviral drugs metabolized by this
system. Conﬂicting results regarding a positive effect
of valproic acid on the eradication of latent virus
reservoirs have been reported (Lehrman et al, 2005;
Siliciano et al, 2007). Table 1a comprehensively sum-
marizes the properties of antiepileptic drugs for the
treatment of HIV-related seizures with special em-
phasis given to their potential of interaction with an-
tiretroviral drugs. The hepatic CYP450 metabolism
of antiretroviral drugs and their inﬂuence on this en-
zyme system is presented in Table 1b, which also
displays the interaction proﬁle of antiretroviral drug
with the currently used antiepileptic drugs.
In HIV-infected patients, imaging studies after
seizures have often been reported as negative with
respect to structural alterations (McArthur et al,
2005). Clonal expansion of HIV quasispecies in
the CNS may account for distinct manifestation of
CNS disease and HIV replication in the CNS may
be independent from other body compartments as
drug mutations distinct from plasma virus can be
detected in CSF (Antinori et al, 2005; Temesgen
et al, 2006). Furthermore, antiretroviral drug pene-
tration into the CNS varies greatly between different
drugs and shows signiﬁcant interindividual variabil-
ity (Antinori et al, 2005; McGee et al, 2006). Our
patient had been on partially suppressive HAART
for 7 years, the last 5 of which he was taking a reg-
imen with overall suboptimal CNS penetration (nel-
ﬁnavir/stavudine/lamivudine). Even though he had
achieved complete suppression of plasma viremia
at time of his second seizure after switching his
antiretrovirals to a more “modern” regimen, lum-
bar puncture revealed poorly controlled HIV repli-
cation in the CNS. Genotypic resistance testing of
the HIV variant isolated from the CSF virus revealed
a resistance pattern distinct from plasma virus. We
decided to adapt the patient’s HAART to specif-
ically target CSF variants, using drugs with opti-
mal CSF/CNS penetration (nevirapine, zidovudine)
or proven efﬁcacy in reducing HIV CNS replication
(lopinavir/ritonavir), accounting for results of geno-
typic resistance testing of the patient’s HIV CSF vari-
ant (Antinori et al, 2005; Thomas, 2004; Van Den
Brande, 2006). This was followed by resolution of
white matter abnormality on MRI and normaliza-
tion of EEG. Follow-up CSF studies demonstrated
resolved CSF pleiocytosis and undetectable CSF vi-
ral load.
This case report highlights the importance of indi-
vidualizing HAART in patients with HIV associated
neurological disease. It also underlines the poten-
tial usefulness of measuring CSF viral load with the
option of genotyping distinct HIV variants. This di-
agnostic approach should be considered in all HIV-
positive patients who undergo lumbar puncture for
CNS disease. It may be of particular interest in pa-
tients taking HAART with suboptimal or poor CSF
penetration.
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Table 1a Pharmacologic proﬁle of currently used antiepileptic drugs with respect to the use in HIV-infected patients under HAART
treatment
Antiepileptic CYP450 Glucuroni- Protein- Risk of Advantages/ Use in HIV-patients
drug∗ metabolism dation binding interaction disadvantages under HAART
Clobazam 2C19 3A4 None 85% Modest Less sedation than other
BD/dependence
Short term: yes
Clonazepam 3A4; inhibits 2B family None 86% Modest Fast + sustained action/
dependence
Emergency use
Diazepam 2C19 3A4 None 97–99% Modest Fast + sustained action/
dependence; several active
metabolites
Emergency use
Lorazepam None Extensive 93% Low Fast + sustained
action/dependence
Emergency and
short-term use
Midazolam 3A4/3A5 45–57% 97% Substantial Very fast, but short action;
1:1 antagonist (ﬂumazenil
dependence
Emergency use
Phenobarbital 2C9 2C19 and 2E1;
substantial CYP
induction: 2B6, 2B8, 2B9,
3A4; induction of UGTs
33% 55% Substantial Broad spectrum; efﬁcacious
extremely cheap/cognitive
impairment; altered mood
and behavior;
hepatotoxicity
Not recommended
Phenytoin 2C9>2C19 3A4
substantial CYP
induction; induction of
UGTs
1% 90% Substantial Broad spectrum; efﬁcacious
cheap/hepatic, bone, and
neurological toxicity; non-
linear pharmacokinetics
Not recommended
Carbamazepine 3A4 > 1A2 and 2C8
substantial CYP
induction; induction of
UGTs
∼50% 70–80% Substantial Very efﬁcacious for focal
seizures; cheap/
neurological side effects;
liver, bone, blood toxicity
Not recommended
Valproic acid 2A6, 2B6, 2C9, 2C19;
substantial inhibitor of
hepatic CYP enzymes;
inhibition of
glucuronidation
10–70% 85–90% Modest Very broad spectrum;
efﬁcacious; modest
price/hepatic toxicity;
hyperammonemia;
thrombocytopenia;
pancreatitis teratogenicity
Recommended;
additional
ant-retroviral effect
Lamotrigine None 70–80% 55% Low Broad spectrum; efﬁcacious;
strong mood stabilizer/
long titration phase; skin
rashes; insomnia
Recommended as
second-line drug
Gabapentin None None None None No interaction; anxiolytic;
effective for neuropathic
pain/restricted
antiepileptic spectrum and
efﬁcacy; elimination
exclusively dependent on
renal function
Recommended
Topiramate Slightly metabolized; weak
inhibition of 2C19; weak
induction of 3A4
40–70% 9–17% Low Broad spectrum; highly
efﬁcacious/cognitive
effects (memory,
language); weight loss;
slow tritration scheme
Recommended as
second-line drug
(cave: weight loss
and cognitive
decline in HIV
patients)
Tiagabine Extensively by 3A4; neither
induction nor inhibition
of CYP
<10% 95% Substantial Few adverse effects/narrow
antiepileptic spectrum;
modest efﬁcacy; may cause
NCSE
Recommended as
third-line drug
Oxcarbazepine Weak secondary CYP-
dependent metabolism;
mainly CYP-independent
reductases
∼70% 40% Low Efﬁcacious; also effective for
neuralgia/hyponatremia
Recommended
Pregabalin None None None None No interaction; anxiolytic;
effective for neuropathic
pain/restricted
antiepileptic spectrum and
efﬁcacy; elimination
exclusively dependent on
renal function
Recommended;
slightly more
effective than
gabapentin; easier
dosage schedule;
for HIV pat.: weight
gain
(Continued on next page)
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Table 1a Pharmacologic proﬁle of currently used antiepileptic drugs with respect to the use in HIV-infected patients under HAART
treatment (Continued)
Antiepileptic CYP450 Glucuroni- Protein- Risk of Advantages/ Use in HIV-patients
drug∗ metabolism dation binding interaction disadvantages under HAART
Levetiracetam None (modest metabolism
by plasma hydrolases)
None None None Broad spectrum; efﬁcacious;
fast titration; signiﬁcant
ﬁrst-dose effect; almost no
adverse effects/dosage
adaptation required for
impaired kidney function
Recommended
Zonisamide Metabolized by
3A4> 2D6> 3A5, 2C19;
neither induction nor
inhibitor!
∼15% 40–60% Modest Broad spectrum;
efﬁcacious/slow titration
Recommended as
second-line drug
∗Felbamate and vigabatrine not listed because of restricted approval due to their serious side-effect proﬁle.
Abbreviations: CYP: cytochrome P450; HIV: human immunodeﬁciency virus; NCSE: nonconvulsive status epilepﬁcus; UGT: uridyl-
glucuronid transferase.
Table 1b CYP metabolism of antiretroviral drugs and potential interactions with antiepileptic drugs
Antiretroviral CYP450 enzymes Induction/ Interaction No interaction
drug involved in metbolism inhibition with AED to expect with
NRTIs
Zidovudine None (glucuronidation) None CBZ, LZP, PB, PHT,
VPA, (DZP, LTG,
TPM)
CLB, CLN, GBP, LEV,
MDL, OXC, PGB,
TGB, ZOS
Abacavir None (glucuronidation,
alcohol;
dehydrogenase)
None CBZ, LZP, PB, PHT,
VPA, (DZP, LTG,
TPM)
CLB, CLN, GBP, LEV,
MDL, OXC, PGB,
TGB, ZOS
Lamivudine None None CBZ, PHT, PB CLB, CLN, DZP, GBP,
LEV, LTG, MDL,
OXC, PGB, TGB,
TPM, VPA, ZOS
Stavudine None None Like lamivudine Like lamivudine
Didanosine None None Like lamivudine Like lamivudine
Zalcitabine None None Like lamivudine Like lamivudine
Tenofovir None Very weak 1A2 Like lamivudine Like lamivudine
NNRTIs
Delavirdine 3A4, 2D6 3A4, 2C9,
2C19/3A4.2C9, 2C19
CBZ, CLB, CLN, DZP,
MDL, PB, PHT, TGB,
VPA, ZOS, (OXC,
TPM)
GBP, LEV, LTG, LZP,
PGB
Efavirenz 3A4, 2B6 3A4, 2B6/2B6,
2C9.2C19, (3A4)
CBZ, CLB, CLN, DZP,
MDL, PB, PHT, TGB,
VPA, ZOS, (OXC,
TPM)
GBP, LEV, LTG, LZP,
PGB
Nevirapine 3A4, 2B6 3A4, 2B6/None CBZ, CLN, MDL, PB,
PHT, TGB, ZOS,
(CLB, DZP, OXC,
TPM, VPA)
GBP,LEV, LTG, LZP
PGB
PIs
Ritonavir 3A4 2D6 1A2, UGTs,
(3A4)/3A4 2D6>2C9>
2C19”2A6>2E1
(2B6), 3A5
CBZ, CLB, CLN, DZP,
LTG, LZP, MDL, OXC,
PB, PHT, TGB, TPM,
VPA, ZOS
GBP, LEV, PGB
Nelﬁnavir 3A4 None/3A4, 2B6, 3A5 CBZ, CLN, MDL, PB,
PHT, TGB, VPA, ZOS,
(CLB, DZP, OXC,
TPM)
GBP, LEV, LTG, LZP,
PGB
Tipranavir 3A4 (3A4)/(3A4) CBZ, CLN, MDL, PB,
PHT, TGB, ZOS (CLB,
DZP, OXC, TPM,
VPA)
GBP, LEV, LTG, LZP,
PGB
Amprenavir 3A4 None/3A4, 3A5, 2C19 CBZ, CLB, CLN, DZP,
MDL, PB, PHT, TGB,
VPA, ZOS, (OXC,
TPM)
GBP, LEV, LTG, LZP,
PGB
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Table 1b CYP metabolism of antiretroviral drugs and potential interactions with antiepileptic drugs (Continued)
Antiretroviral CYP450 enzymes Induction/ Interaction No interaction
drug involved in metbolism inhibition with AED to expect with
Atazanavir 3A4 None/3A4, UGT1A1 CBZ, CLN, LTG, LZP,
MDL, PB, PHT, TGB,
VPA, ZOS, (CLB,
DZP, OXC, TPM)
GBP, LEV, PGB
Indinavir 3A4 None/(weak) 3A4 Like tipranavir Like tipranavir
Saquinavir 3A4 None/(weak) 3A4, 3A5 Like tipranavir Like tipranavir
Lopinavir 3A4 None/3A4 Like tipranavir Like tipranavir
Darunavir 3A4 (/5) ? Like pranavir (?) Like tipranavir (?)
FIs
Enfuvirtide None None/None None (?) All antiepileptic drugs
Abbreviations: NRTIs: nucleoside/tide reverse transcriptase inhibitors; NNRTIs: non-nucleoside reverse transcriptase inhibitors; PIs:
protease inhibitors; FIs: fusion inhibitors.
Antiepileptic drugs: CBZ: carbamazepine; CLB: clobazam; CLN: clonazepam; DZP: diazepam; GBP: gabapentin; LEV: levetiracetam;
LTG: lamotrigine; LZP: lorazepam; MDL: midazolam; OXC: oxcarbazepine; PB: phenobarbital; PHT: phenytoin; PGB: pregabalin; TGB:
tiagabine; TPM: topiramate; VPA: valproic acid; ZOS: zonisamide.
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